CL2021000819A1 - Administración sostenida de polipéptidos similares a la angiopoyetina 3 - Google Patents
Administración sostenida de polipéptidos similares a la angiopoyetina 3Info
- Publication number
- CL2021000819A1 CL2021000819A1 CL2021000819A CL2021000819A CL2021000819A1 CL 2021000819 A1 CL2021000819 A1 CL 2021000819A1 CL 2021000819 A CL2021000819 A CL 2021000819A CL 2021000819 A CL2021000819 A CL 2021000819A CL 2021000819 A1 CL2021000819 A1 CL 2021000819A1
- Authority
- CL
- Chile
- Prior art keywords
- drug delivery
- delivery systems
- angiopoietin
- polypeptides
- sustained administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En este documento, se describen sistemas de administración de fármacos para administrar agentes biológicamente activos que comprenden aminas primarias o secundarias, o un átomo de nitrógeno de anillo de un anillo azaheteroarilo, sales farmacéuticamente aceptables de los mismos, reactivos de administración de fármacos relacionados con el mismo, composiciones farmacéuticas que comprenden los sistemas de administración de fármacos y el uso de los sistemas de administración de fármacos como terapéutica de liberación sostenida
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862740609P | 2018-10-03 | 2018-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000819A1 true CL2021000819A1 (es) | 2021-11-12 |
Family
ID=68165677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000819A CL2021000819A1 (es) | 2018-10-03 | 2021-03-31 | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
Country Status (25)
Country | Link |
---|---|
US (2) | US11389541B2 (es) |
EP (1) | EP3860657A1 (es) |
JP (2) | JP7336513B2 (es) |
KR (1) | KR20210066860A (es) |
CN (1) | CN112770782A (es) |
AR (1) | AR116566A1 (es) |
AU (1) | AU2019353174A1 (es) |
BR (1) | BR112021005981A2 (es) |
CA (1) | CA3112251A1 (es) |
CL (1) | CL2021000819A1 (es) |
CO (1) | CO2021004012A2 (es) |
CR (1) | CR20210156A (es) |
CU (1) | CU20210022A7 (es) |
DO (1) | DOP2021000053A (es) |
EA (1) | EA202190650A1 (es) |
EC (1) | ECSP21022120A (es) |
IL (1) | IL281227A (es) |
JO (1) | JOP20210061A1 (es) |
MX (1) | MX2021003839A (es) |
PE (1) | PE20211646A1 (es) |
PH (1) | PH12021550675A1 (es) |
SG (1) | SG11202102076TA (es) |
TW (1) | TW202027794A (es) |
WO (1) | WO2020070675A1 (es) |
ZA (1) | ZA202101419B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220005561A (ko) * | 2019-05-07 | 2022-01-13 | 젠자임 코포레이션 | 전구약물 조성물에서 약물 농도를 정량화하는 방법 |
CN112220963B (zh) * | 2020-09-24 | 2022-05-24 | 哈尔滨工业大学 | 一种非溶胀uv交联壳聚糖可注射水凝胶及其合成方法 |
TW202306970A (zh) | 2021-05-24 | 2023-02-16 | 瑞士商諾華公司 | 用於治療骨關節炎之方法 |
WO2022249040A1 (en) | 2021-05-24 | 2022-12-01 | Novartis Ag | Methods for the treatment of osteoarthritis |
WO2024044608A1 (en) * | 2022-08-23 | 2024-02-29 | Astellas Institute For Regenerative Medicine | Cell cryopreservative formulations and methods of use |
CN117379362A (zh) * | 2023-10-11 | 2024-01-12 | 首都医科大学附属北京潞河医院 | 负载血管生成素样蛋白3的水凝胶及其制备方法与应用 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308236D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
DE3737523A1 (de) | 1987-11-05 | 1989-05-18 | Bayer Ag | Verwendung von substituierten hydroxypiperidinen als antivirale mittel |
US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
US5288931A (en) | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
DE69530553T2 (de) | 1994-05-13 | 2004-03-25 | KURARAY CO., LTD, Kurashiki | Medizinisches polymergel |
AU4172397A (en) | 1996-09-06 | 1998-03-26 | Biochem Pharma Inc. | Lactam inhibitors of thrombin |
WO1999058660A1 (en) | 1998-05-12 | 1999-11-18 | Human Genome Sciences, Inc. | 97 human secreted proteins |
US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
WO1999055869A1 (en) | 1998-04-27 | 1999-11-04 | Zymogenetics, Inc. | Novel polypeptide growth factors and materials and methods for making them |
WO1999067382A2 (en) | 1998-06-24 | 1999-12-29 | Compugen Ltd. | Angiopoietin-like growth factor sequences |
CA2346329A1 (en) | 1998-10-09 | 2000-04-20 | Kamal H. Bouhadir | Hydrogels and water soluble polymeric carriers for drug delivery |
CA2361849A1 (en) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
GB9912350D0 (en) | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
CA2375458A1 (en) | 1999-07-20 | 2001-01-25 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
US20040249141A1 (en) | 2000-10-16 | 2004-12-09 | Audrey Goddard | Tie ligand homologues |
AU2002224377B2 (en) | 2000-10-16 | 2007-07-19 | Genentech, Inc. | Methods of Treatment Using WISP Polypeptides |
CA2432988A1 (en) | 2001-01-23 | 2002-08-01 | Cristina Garcia-Paredes | Melanocortin receptor agonists |
US20030027751A1 (en) | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
FI117667B (fi) | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
CN101905024A (zh) | 2001-11-16 | 2010-12-08 | 杰南技术公司 | 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法 |
WO2004022630A2 (en) | 2002-09-09 | 2004-03-18 | Nektar Therapeutics Al, Corporation | Water-soluble polymer alkanals |
WO2005028502A1 (en) | 2003-09-18 | 2005-03-31 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
CA2786794C (en) | 2004-03-23 | 2017-09-12 | Complex Biosystems Gmbh | Aromatic polymeric cascade prodrug linker reagent |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
EP1863340A2 (en) | 2005-03-11 | 2007-12-12 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
JP5139271B2 (ja) | 2005-05-24 | 2013-02-06 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | 培養した造血幹細胞を拡大しかつ分析する方法 |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
CA2614049C (en) | 2005-07-06 | 2014-12-02 | Molly S. Shoichet | Method of biomolecule immobilization on polymers using click-type chemistry |
US20070060658A1 (en) | 2005-08-31 | 2007-03-15 | Diaz David D | Stabilization of organogels and hydrogels by azide-alkyne [3+2] cycloaddition |
ITMI20061726A1 (it) | 2006-09-11 | 2008-03-12 | Fidia Farmaceutici | Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry |
KR101460815B1 (ko) | 2006-12-06 | 2014-11-12 | 세이가가쿠 고교 가부시키가이샤 | 관절염 질환 치료의 지속성 효과를 갖는 제약 제제 |
HUE033960T2 (en) | 2006-12-08 | 2018-01-29 | Lexicon Pharmaceuticals Inc | Monoclonal Antibodies to ANGPTL3 |
CA2677487A1 (en) | 2007-02-09 | 2008-08-14 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
CA2682483A1 (en) | 2007-03-29 | 2008-10-09 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
EP2155862A2 (en) | 2007-05-04 | 2010-02-24 | Whitehead Institute For Biomedical Research | Ex vivo expansion of human hematopoietic stem cells |
US9353170B2 (en) | 2007-06-08 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Long-acting transient polymer conjugates of exendin |
WO2009095954A2 (ja) | 2008-01-31 | 2009-08-06 | Appside Co., Ltd. | データ入力装置、データ入力方法ならびにデータ入力プログラムおよびこれを記録した記録媒体 |
US8906847B2 (en) | 2008-02-01 | 2014-12-09 | Ascendis Pharma A/S | Prodrug comprising a drug linker conjugate |
JP2012508238A (ja) | 2008-11-07 | 2012-04-05 | ハー・ルンドベック・アクチエゼルスカベット | 生物活性を有するアミド |
US8133979B2 (en) | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
WO2010095049A1 (en) | 2009-02-21 | 2010-08-26 | Sofradim Production | Crosslinked fibers and method of making same by extrusion |
WO2010099818A1 (en) | 2009-03-03 | 2010-09-10 | Ao Technology Ag | Thermoreversible polysaccharide hydrogel |
WO2010102663A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Piperazine derivatives for use in therapy |
IN2012DN00352A (es) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
TW201113280A (en) | 2009-07-03 | 2011-04-16 | Nensius Res As | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the CNS |
JP5602850B2 (ja) | 2009-07-14 | 2014-10-08 | ザ スクリプス リサーチ インスティテュート | 間葉幹細胞分化 |
RU2554854C9 (ru) | 2009-07-31 | 2017-02-03 | Асцендис Фарма Ас | Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля |
WO2011012723A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Injectable sustained release compositions comprising a pramipexole prodrug |
EP2459225A1 (en) | 2009-07-31 | 2012-06-06 | Ascendis Pharma A/S | Carrier linked pramipexole prodrugs |
WO2011012718A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Prodrugs comprising an insulin linker conjugate |
EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
BR112012001988A2 (pt) | 2009-07-31 | 2017-05-09 | Sanofi Aventis Deutschland | composição de insulina de ação prolongada |
WO2011042450A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Carrier linked paliperidone prodrugs |
US8758780B2 (en) | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
NZ599583A (en) | 2009-10-29 | 2013-09-27 | Ascendis Pharma As | Sterilization of biodegradable hydrogels |
EP2525829A1 (en) | 2010-01-22 | 2012-11-28 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
US9561285B2 (en) | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
CN107235828B (zh) | 2010-04-27 | 2024-06-07 | 西纳福克斯股份有限公司 | 稠合的环辛炔化合物及其在无金属点击反应中的应用 |
US8946405B2 (en) | 2010-05-05 | 2015-02-03 | Prolynx Llc | Controlled release from solid supports |
EA025611B1 (ru) | 2010-07-29 | 2017-01-30 | Райджел Фармасьютикалз, Инк. | Активирующие ampk гетероциклические соединения и способы их использования |
DK2670847T3 (en) | 2011-02-03 | 2017-01-16 | Xoma Technology Ltd | Methods and Materials for Improving Functional Protein Expression in Bacteria |
WO2012116250A1 (en) | 2011-02-25 | 2012-08-30 | University Of Massachusetts Medical School | Monomers and polymers for functional polycarbonates and poly (ester-carbonates) and peg-co-polycarbonate hydrogels |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
CZ304072B6 (cs) | 2011-04-26 | 2013-09-25 | Contipro Biotech S.R.O. | Amfoterní materiál na bázi sítované kyseliny hyaluronové, zpusob jeho prípravy, materiály obsahující aktivní cinidla uzavrené v síti hyaluronanu, zpusob jejich prípravy a jejich pouzití |
US20140256831A1 (en) | 2011-05-31 | 2014-09-11 | The University Of Tokyo | Hydrogel and method for producing same |
US9428478B2 (en) | 2011-06-13 | 2016-08-30 | Emory University | Piperazine derivatives, compositions, and uses related thereto |
JP2014522878A (ja) | 2011-08-12 | 2014-09-08 | アセンディス ファーマ エー/エス | プロスタサイクリンの徐放組成物 |
KR102226702B1 (ko) | 2011-09-07 | 2021-03-11 | 프로린크스 엘엘시 | 생분해성 교차결합을 가지는 하이드로젤 |
US20130066063A1 (en) | 2011-09-09 | 2013-03-14 | John Cooke Hodges | Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides |
JP2014528465A (ja) | 2011-10-12 | 2014-10-27 | アセンディス ファーマ オフサルモロジー ディヴィジョン エー/エス | 眼の状態の予防及び治療 |
CA2857548A1 (en) | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Targeted enzyme compounds and uses thereof |
CN104145015A (zh) | 2011-12-01 | 2014-11-12 | 安吉奥开米公司 | 靶向的溶酶体酶化合物 |
JP2013116858A (ja) | 2011-12-01 | 2013-06-13 | Dainippon Sumitomo Pharma Co Ltd | Bdnf様低分子化合物を含有する治療薬 |
US20150148525A1 (en) | 2012-05-18 | 2015-05-28 | Medical Research Council | Methods of incorporating an amino acid comprising a bcn group into a polypeptide using an orthogonal codon encoding it and an orthorgonal pylrs synthase |
PT2864360T (pt) | 2012-06-25 | 2018-01-05 | The Brigham And Women`S Hospital Inc | Terapêuticas dirigidas ao alvo |
WO2014056915A1 (en) | 2012-10-11 | 2014-04-17 | Ascendis Pharma A/S | Diagnosis, prevention and treatment of diseases of the joint |
CA2884910C (en) | 2012-10-11 | 2021-07-13 | Ascendis Pharma Ophthalmology Division A/S | Vegf neutralizing prodrugs for the treatment of ocular conditions |
WO2014056926A1 (en) | 2012-10-11 | 2014-04-17 | Ascendis Pharma A/S | Hydrogel prodrugs |
US20150267196A1 (en) | 2012-10-12 | 2015-09-24 | Case Western Reserve University | Biodegradable hydrogel for polynucleotide delivery |
US20150352246A1 (en) | 2013-01-22 | 2015-12-10 | Prolynx Llc | Sealants having controlled degration |
US9301971B2 (en) | 2013-03-08 | 2016-04-05 | Novartis Ag | Peptides and compositions for treatment of joint damage |
UY35368A (es) | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
AP2015008656A0 (en) | 2013-03-15 | 2015-08-31 | Novartis Ag | Antibody drug conjugates |
WO2014173759A1 (en) | 2013-04-22 | 2014-10-30 | Ascendis Pharma A/S | Hydrogel-linked prodrugs releasing modified drugs |
JP6311008B2 (ja) | 2013-04-22 | 2018-04-11 | アセンディス ファーマ エー/エス | 修飾されたヒドロゲル |
WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
CN104292454B (zh) | 2013-07-17 | 2017-12-01 | 北京键凯科技股份有限公司 | 聚乙二醇‑环辛炔衍生物 |
JP2016172783A (ja) | 2013-08-08 | 2016-09-29 | 生化学工業株式会社 | 組織膨隆材 |
US20180042996A1 (en) | 2013-10-08 | 2018-02-15 | Ascendis Pharma Osteoarthritis Division A/S | Hydrogel-Linked IL-1ra Prodrug |
CA2928407A1 (en) | 2013-10-22 | 2015-04-30 | Prolynx Llc | Conjugates of somatostatin and its analogs |
CA2929201A1 (en) | 2013-11-11 | 2015-05-14 | Ascendis Pharma Relaxin Division A/S | Relaxin prodrugs |
US20170182220A1 (en) | 2014-02-26 | 2017-06-29 | University Of Massachusetts | Degradable hydrogel with predictable tuning of properties, and compositions and methods thereof |
CA2955569C (en) | 2014-08-06 | 2023-02-14 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
WO2016025752A1 (en) | 2014-08-14 | 2016-02-18 | Prolynx Llc | Reagents for thiol conjugation and conjugates formed therefrom |
TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
BR112017014560A2 (pt) | 2015-01-09 | 2018-01-02 | Ascendis Pharma Growth Disorders As | profármacos de cnp |
MA41794A (fr) * | 2015-03-18 | 2018-01-23 | The California Institute For Biomedical Res | Agents thérapeutiques modifiés et compositions associées |
WO2016196124A2 (en) | 2015-05-29 | 2016-12-08 | Ascendis Pharma Inc. | Prodrugs comprising a pyroglutamate linker |
BR112018010205A2 (pt) | 2015-11-20 | 2018-11-21 | Cristal Delivery B V | nanopartículas com direcionamento ativo |
EP3922269A1 (en) | 2016-03-16 | 2021-12-15 | Prolynx LLC | Extended release conjugates of exenatide analogs |
AU2017295938C1 (en) | 2016-07-13 | 2021-10-07 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
-
2019
- 2019-10-01 TW TW108135606A patent/TW202027794A/zh unknown
- 2019-10-01 AR ARP190102781A patent/AR116566A1/es unknown
- 2019-10-02 JP JP2021517752A patent/JP7336513B2/ja active Active
- 2019-10-02 CR CR20210156A patent/CR20210156A/es unknown
- 2019-10-02 EP EP19783723.0A patent/EP3860657A1/en active Pending
- 2019-10-02 EA EA202190650A patent/EA202190650A1/ru unknown
- 2019-10-02 CU CU2021000022A patent/CU20210022A7/es unknown
- 2019-10-02 WO PCT/IB2019/058400 patent/WO2020070675A1/en active Application Filing
- 2019-10-02 MX MX2021003839A patent/MX2021003839A/es unknown
- 2019-10-02 US US16/591,053 patent/US11389541B2/en active Active
- 2019-10-02 KR KR1020217012201A patent/KR20210066860A/ko not_active Application Discontinuation
- 2019-10-02 JO JOP/2021/0061A patent/JOP20210061A1/ar unknown
- 2019-10-02 BR BR112021005981-4A patent/BR112021005981A2/pt unknown
- 2019-10-02 CN CN201980064248.5A patent/CN112770782A/zh active Pending
- 2019-10-02 CA CA3112251A patent/CA3112251A1/en active Pending
- 2019-10-02 AU AU2019353174A patent/AU2019353174A1/en active Pending
- 2019-10-02 SG SG11202102076TA patent/SG11202102076TA/en unknown
- 2019-10-02 PE PE2021000422A patent/PE20211646A1/es unknown
-
2021
- 2021-03-02 ZA ZA2021/01419A patent/ZA202101419B/en unknown
- 2021-03-03 IL IL281227A patent/IL281227A/en unknown
- 2021-03-25 PH PH12021550675A patent/PH12021550675A1/en unknown
- 2021-03-30 EC ECSENADI202122120A patent/ECSP21022120A/es unknown
- 2021-03-30 CO CONC2021/0004012A patent/CO2021004012A2/es unknown
- 2021-03-30 DO DO2021000053A patent/DOP2021000053A/es unknown
- 2021-03-31 CL CL2021000819A patent/CL2021000819A1/es unknown
-
2022
- 2022-05-26 US US17/804,217 patent/US20220323595A1/en not_active Abandoned
-
2023
- 2023-07-06 JP JP2023111526A patent/JP2023145478A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200108153A1 (en) | 2020-04-09 |
CN112770782A (zh) | 2021-05-07 |
US20220323595A1 (en) | 2022-10-13 |
CO2021004012A2 (es) | 2021-04-19 |
EP3860657A1 (en) | 2021-08-11 |
JP2023145478A (ja) | 2023-10-11 |
AU2019353174A1 (en) | 2021-04-01 |
IL281227A (en) | 2021-04-29 |
CA3112251A1 (en) | 2020-04-09 |
CR20210156A (es) | 2021-04-28 |
ZA202101419B (en) | 2022-07-27 |
PH12021550675A1 (en) | 2022-01-03 |
JOP20210061A1 (ar) | 2023-01-30 |
CU20210022A7 (es) | 2021-10-12 |
JP2022501406A (ja) | 2022-01-06 |
EA202190650A1 (ru) | 2021-07-21 |
PE20211646A1 (es) | 2021-08-24 |
MX2021003839A (es) | 2021-05-27 |
AR116566A1 (es) | 2021-05-19 |
DOP2021000053A (es) | 2021-04-30 |
ECSP21022120A (es) | 2021-04-29 |
BR112021005981A2 (pt) | 2021-06-29 |
SG11202102076TA (en) | 2021-04-29 |
JP7336513B2 (ja) | 2023-08-31 |
WO2020070675A1 (en) | 2020-04-09 |
US11389541B2 (en) | 2022-07-19 |
TW202027794A (zh) | 2020-08-01 |
KR20210066860A (ko) | 2021-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19075134A (es) | Sistemas de administración de liberación sostenida que comprenden ligantes que no dejan huellas | |
CL2021000819A1 (es) | Administración sostenida de polipéptidos similares a la angiopoyetina 3 | |
ECSP22047876A (es) | Derivados de pirazolilo ?tiles como agentes anticancer?genos | |
BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
CL2023000176A1 (es) | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este | |
BR112018005589A2 (pt) | “composto, composição farmaceuticamente aceitável, e, uso de um composto” | |
CO2022004723A2 (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
BR112018072113A2 (pt) | excipiente à base de proteínas para ingredientes farmacêuticos ativos | |
CL2020001817A1 (es) | Moduladores del receptor c5a | |
BR112022022669A2 (pt) | Inibidores de nek7 quinase | |
EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
DOP2022000057A (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
CO2022009510A2 (es) | Compuestos activos frente a receptores nucleares | |
ECSP21067816A (es) | Formulaciones farmacéuticas | |
DOP2021000103A (es) | Pirazoles como moduladores de hemoglobina | |
UY37412A (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos | |
CL2019002899A1 (es) | Formulaciones con mayor estabilidad y biodisponibilidad para administración de (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas en 4. | |
CL2022002932A1 (es) | Composiciones y métodos para suministrar agentes farmacéuticamente activos | |
UY36958A (es) | Compuestos para administración intracelular | |
AR117298A1 (es) | Aglutinante de péptido | |
MX2019003229A (es) | Formulaciones liquidas estables. |